5 completed. 4 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 4 | Completed 4 |
| Phase 2 | 1 | Completed 1 |
Follow DC-806: new trials by email Literature Review of DC-806 trials Research Report on DC-806
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Drug-Drug Interaction Study Evaluating the Perpetrator Potential of DC-806 on Cocktails of CYP450 Enzyme and Transporter Substrates in Healthy Participants DC-806, Midazolam, Repaglinide - Healthy Participants | Phase 1 | Completed | DICE Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and Company | 28 | 2023-10-16 | 2026-10-19 |
| Mass Balance and Pharmacokinetics (PK) of [14C]-DC-806 in Healthy Male Participants DC-806, [14C]-DC-806 - Healthy Volunteers | Phase 1 | Completed | DICE Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and Company | 8 | 2023-09-14 | 2025-05-04 |
| A Drug-Drug Interaction Study to Assess the Pharmacokinetics of DC-806 When Orally Administered Alone, When Coadministered With Itraconazole, and When Coadministered With Carbamazepine in Healthy Adult Participants DC-806, Itraconazole, Carbamazepine - Healthy Volunteers | Phase 1 | Completed | DICE Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and Company | 33 | 2023-08-08 | 2026-10-19 |
| A Study to Evaluate the Efficacy and Safety of DC-806 in Participants With Moderate to Severe Plaque Psoriasis DC-806, Placebo - Plaque Psoriasis | Phase 2 | Completed | DICE Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and Company | 229 | 2023-05-02 | 2025-04-04 |
| A Study to Assess S011806 (DC-806 or LY4100504) in Healthy Adult Participants and Participants With Chronic Plaque Psoriasis DC-806, Placebo - Plaque Psoriasis | Phase 1 | Completed | DICE Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and Company | 104 | 2021-09-22 | 2025-02-05 |
DICE Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and Company (5)
United States (3) · United Kingdom (2) · Canada (1) · Czechia (1) · Germany (1) · Hungary (1) · Netherlands (1) · Poland (1) · Spain (1)
2023 (1)